Living with the burden of relapse in multiple myeloma from the patient and physician perspective
Cyrille Hulin(Hôpital Cardiologique du Haut-Lévêque), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Ananda Plate(European Federation of Allergy and Airways Diseases Patients Associations), Antoine Tinel(Bristol-Myers Squibb (France)), Sue Perkins(Myeloma UK), Kate Morgan(Association des Operateurs Postaux Publics Europeens), Matthew Streetly(King's College - North Carolina), Timon Hansen(Universität Hamburg), Rachel Pughe(Adelphi Group (United Kingdom)), Filipe Rodrigues, Louise Heron(Adelphi Group (United Kingdom))
Cited by 44
Related Papers
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2023|538
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
|Journal of Clinical Oncology|2004|315